Department of Cardiology, Xinxin Hospital of Qijiang District.
Department of Neurology, Daping Hospital, Army Medical University, Chongqing, China.
Clin Neuropharmacol. 2020 Jul/Aug;43(4):107-111. doi: 10.1097/WNF.0000000000000401.
The efficacy of DFN-15 for pain control of migraine remains controversial. We conduct a systematic review and meta-analysis to explore the influence of DFN-15 versus placebo on pain control in migraine patients.
We search PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases through November 2019 for randomized controlled trials assessing the effect of DFN-15 versus placebo on pain control in migraine patients. This meta-analysis is performed using the random-effects model.
Three randomized controlled trials are included in the meta-analysis. Overall, compared with the control group in migraine patients, lasmiditan treatment shows a positive impact on pain freedom at 2 hours (risk ratio [RR], 1.96; 95% confidence interval, 1.61-2.40; P < 0.00001), headache response at 2 hours (RR, 1.40; 95% CI, 1.25-1.57; P < 0.00001), and pain freedom at 24 hours (RR, 1.87; 95% CI, 1.33-2.62; P = 0.0003), but has no obvious influence or no substantial impact on no or mild disability level (RR, 1.21; 95% CI, 0.97-1.52; P = 0.09) or nausea (RR, 2.42; 95% CI, 0.53-11.01; P = 0.25). In addition, lasmiditan seems to result in the increase in dizziness (RR, 7.33; 95% CI, 1.83-29.30; P = 0.005) and paresthesia (RR, 5.17; 95% CI, 2.08-12.86; P = 0.0004).
DFN-15 treatment may be effective and safe for pain control in migraine patients.
DFN-15 控制偏头痛疼痛的疗效仍存在争议。我们进行了一项系统评价和荟萃分析，以探究 DFN-15 与安慰剂相比对偏头痛患者疼痛控制的影响。
我们通过检索 PubMed、Embase、Web of Science、EBSCO 和 Cochrane Library 数据库，检索时间截至 2019 年 11 月，以评估 DFN-15 与安慰剂相比对偏头痛患者疼痛控制效果的随机对照试验。本荟萃分析采用随机效应模型进行。
共有 3 项随机对照试验纳入荟萃分析。总体而言，与偏头痛患者的对照组相比，拉米替坦治疗在 2 小时时对疼痛无缓解（风险比 [RR]，1.96；95%置信区间 [CI]，1.61-2.40；P<0.00001）、2 小时时头痛缓解（RR，1.40；95%CI，1.25-1.57；P<0.00001）和 24 小时时疼痛无缓解（RR，1.87；95%CI，1.33-2.62；P=0.0003）有积极影响，但对无或轻度残疾水平（RR，1.21；95%CI，0.97-1.52；P=0.09）或恶心（RR，2.42；95%CI，0.53-11.01；P=0.25）无明显影响或无实质性影响。此外，拉米替坦似乎导致头晕（RR，7.33；95%CI，1.83-29.30；P=0.005）和感觉异常（RR，5.17；95%CI，2.08-12.86；P=0.0004）的发生率增加。
DFN-15 治疗可能对偏头痛患者的疼痛控制有效且安全。
